Clinical Trial Update: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations [Phase 2]

View source ↗

Summary

BEBT-109 is being studied in non-small cell lung cancer with EGFR exon 20 insertion mutations in a Phase 2 trial, which is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BEBT-109 (BEBT-109)

Snippet

Sponsor: BeBetter Med Inc | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING